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Abstract
Hemifacial microsomia (HFM) is the second most common facial anomaly after cleft lip and palate. The phenotype is highly
variable and most cases are sporadic. We investigated the disorder in a large pedigree with five affected individuals
spanning eight meioses. Whole-exome sequencing results indicated the absence of a pathogenic coding point mutation. A
genome-wide survey of segmental variations identified a 1.3 Mb duplication of chromosome 14q22.3 in all affected
individuals that was absent in more than 1000 chromosomes of ethnically matched controls. The duplication was absent in
seven additional sporadic HFM cases, which is consistent with the known heterogeneity of the disorder. To find the critical
gene in the duplicated region, we analyzed signatures of human craniofacial disease networks, mouse expression data, and
predictions of dosage sensitivity. All of these approaches implicated OTX2 as the most likely causal gene. Moreover, OTX2 is
a known oncogenic driver in medulloblastoma, a condition that was diagnosed in the proband during the course of the
study. Our findings suggest a role for OTX2 dosage sensitivity in human craniofacial development and raise the possibility of
a shared etiology between a subtype of hemifacial microsomia and medulloblastoma.
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Introduction
Hemifacial microsomia (HFM; also termed oculoauriculover-
tebral spectrum or Goldenhar syndrome, OMIM: 164210) is a
highly heterogeneous condition with an estimated rate of 1 in
5,600 to 20,000 births [1]. The hallmarks of this disorder are
marked facial asymmetry due to maxillary and mandibular
hypoplasia and ear malformations such as preauricular skin tags,
microtia, anotia, and conductive hearing loss. Some cases also
present epibulbar dermoids and coloboma of the upper eyelid,
cleft lip and palate, as well as cardiac, renal, and vertebral defects.
To a lesser extent, the disorder also involves neurological
anomalies and developmental delays or mental retardation [1–3].
The characteristic facial anomalies of HFM cases are attributed
to disruptions in the first and second pharyngeal arches during
days 30–45 of gestation in humans [1]. These arches contribute to
the development of muscles of mastication, the maxilla, the
mandible, middle ear bones, muscles of facial expression, and the
stapedial artery. Animal models suggest embryonic hemorrhage or
a deficiency in neural crest cell migration as the pathogenesis,
which can disrupt normal development of pharyngeal arch derived
structures [4].
The HFM spectrum reflects a complex pathogenesis that
presumably includes both extrinsic and genetic risk factors [2].
Several epidemiological surveys suggest a role for environmental
factors that affect the vascular system, including use of vasoactive
agents, hypoxia, exposure to teratogens, and gestational diabetes
[5]. While most HFM cases are sporadic, approximately 2–10% of
cases are familial and occur in more than one generation,
supporting the contribution of genetic risk factors [6,7]. Careful
examination of seemingly unaffected relatives of a large number of
probands revealed familial aggregation of mild craniofacial
malformations and preauricular skin tags [8]. These mild features
are relatively rare in the general population but do not meet the
clinical criteria for HFM, leading to a decreased perception of
family history. Segregation analysis of 74 families strongly favored
an autosomal dominant mode of inheritance with incomplete
penetrance over recessive or polygenic transmission [9]. These
results suggest that genetics plays a broad etiological role in the
manifestation of the disorder.
Genetic investigations of HFM cases have not yet clearly
defined the critical genes involved in this disorder. Several studies
have reported facial asymmetry and mandibular hypoplasia in
cases with gross chromosomal aberrations and trisomies [10–15].
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However, these patients exhibited multi-organ pathologies atypical
of most HFM cases, suggesting distinct syndromes. Genome-wide
linkage analysis of 3 HFM pedigrees revealed potential linkage to
14q32, 11q12–13 [16], and 15q26.2-q26.3 [17] but candidate
gene sequencing in these studies failed to find a pathogenic
variation. Rooryck et al. [18] performed array CGH on a cohort
of 86 HFM patients, most without family history of the disorder.
They found 12 copy number variants (CNVs) ranging from 2.7 kb
to 2.3 Mb (median: 153 Kb). However, none of these CNVs were
recurrent and 9 out of the 10 autosomal CNVs were also present
in unaffected individuals. The authors concluded that it is difficult
to interpret to what extent these CNVs contribute to the disorder.
To date, the field has yet to identify a strong etiological gene that is
responsible for the pathogenesis of the disorder.
We conducted a systematic analysis to identify an etiological
variant of HFM. To increase the power of the investigation, we
focused on a large family with multiple affected individuals. To the
best of our knowledge, this family is the largest HFM kinship to
date that is described in the literature. We considered both exonic
mutations and copy number variations to further increase the
probability of identifying the etiological locus while excluding
bystander variations [19]. This process revealed a segmental
duplication of 8 genes that segregates with the disorder. An
unbiased HFM disease network analysis and expression profiling
implicate OTX2 as the pathogenic gene in the CNV.
Results
Clinical presentation
We identified a five generation Ashkenazi kinship that displays
variable HFM anomalies in five individuals separated by a total of
eight meiosis events (Figure 1, Table 1). In all cases, the family
denied consanguinity and the disorder appears to follow an
autosomal dominant segregation pattern with incomplete pene-
trance and variable expressivity.
The proband, subject V.3, was presented to the Craniofacial
Department of the Rambam Medical Center in Israel at the age of
three. She was born after normal pregnancy (42 weeks) and
caesarian delivery. Clinical examination revealed mandibular
hypoplasia and facial asymmetry, cleft #7 according to Tessier’s
craniofacial classification system, preauricular skin tags, and grade
II microtia, all on the right side. Deafness in the right ear was
diagnosed at the age of 2 months. She is of normal intelligence and
no other abnormalities were noted at the time (Figure 1,
Table 1). The proband underwent a combined surgical ortho-
dontic manipulation using the distraction osteogenesis technique
to elongate the right mandibular ramus. During the course of this
study, at age seven, she was diagnosed with a medulloblastoma in
the fourth ventricle. The tumor was completely resected, after
which the child received craniospinal radiotherapy and chemo-
therapy [see a case study on her cancer treatment [20]].
The proband’s mother (IV.3), grandmother (III.1) and cousin
(V.2) were also examined at the Craniofacial Department of the
Rambam Medical Center. All individuals exhibited milder facial
asymmetry with unilateral clefts and preauricular skin tags without
ear involvement. Examination of the proband’s uncle (IV.2) did
not reveal any facial anomalies, indicating incomplete penetrance
of the disorder.
The proband’s first cousin twice removed (III.3) was identified
at a later stage of the study. He presented mild facial asymmetry
on his left side without auricle involvement and reported that his
grandmother (I.1) displayed similar features.
Analysis of exonic variants showed no evidence of causal
point mutation
We performed whole exome sequencing of individuals III.1,
V.2, and V.3. The average autosomal coverage of the targeted
regions in the three samples was 956-1056 reads per base pair.
More than 96% of each exome was covered by at least one read
(Figure S1, Table S2). Exome sequencing revealed 22,252,
22,746, and 23,175 exonic variants in III.1, V.2, and V.3
respectively. We observed transition/transversion ratios of 2.89–
3.00 and homozygous to heterozygous mutation ratios of 0.56–
0.58. In parallel, we also conducted genome-wide genotyping of
Figure 1. The five-generation pedigree. The family consists of five affected individuals spanning eight meioses. The proband (V.3) is indicated by
an arrow. We were able to obtain consent from individuals IV.3 and V.3 to publish photos.
doi:10.1371/journal.pone.0096788.g001
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these three samples using the Affymetrix SNP Array 6.0.
Comparing shared variations between the two platforms showed
concordance rates of more than 98% for non-reference loci
(Table S1). All of these technical indicators are consistent with the
results of previous studies [21–23], supporting the quality of the
exome sequencing data.
We passed the exonic variations through a series of filters to find
mutations that fit the rare familial pathology (Table 2). First, we
excluded synonymous variants. Second, we excluded variations
that appear at a frequency greater than 0.1% in large-scale
sequencing projects such as the Exome Sequencing Project, 1000
Genomes, and ClinSeq, as documented in dbSNP. In addition, we
excluded variations that appeared at least twice in the exome
sequencing data of 21 healthy Ashkenazi Jews (provided by Noam
Shomron, Tel Aviv University). In the Appendix, we show that
these frequency cutoffs are very conservative. Third, we focused
only on variants that reside in regions that are identical by descent
(IBD) in all individuals. Variants that reside in these haplotypes
were transmitted from III.1 to V.2 and V.3. Shared variants
outside these regions are from ancient coalescent events and reflect
inheritance patterns that do not segregate with the phenotype.
Using genome-wide genotype data, we identified 33 autosomal
segments that are IBD in these three individuals, with a total size
of 421.2 Mb (14.5% of the autosome). This value is close to the
theoretical expectation of a familial relationship of one grand-
mother and two cousins (1/461/2= 12.5% on average). After
excluding exonic variations that fall outside these segments, the
number of plausible candidates was reduced to 84, 90, and 72
variations in III.1, V.2, and V.3. Finally, we retained only
variations in the IBD segments that appear in all three individuals
(Table S3), which resulted in 41 candidates (26 SNPs and 15
indels). Only 4 of these variations were not documented in dbSNP.
At this stage, we were able to recruit individual III.3 to the
study. We conducted array-based genome-wide genotyping and
used the results to determine shared segments that are IBD in all
four individuals: III.1, III.3, V.2, and V.3. This process resulted in
16 segments with a total length of 59 Mb (2.0% of the autosome
that is shared between all four individuals). Again, this number is
close to the theoretical expectation of 1/461/461/4=1.6%.
Excluding variants outside these regions returned zero shared
candidates. This filtering process showed that there is no single
non-synonymous point mutation of relatively rare frequency in the
population that segregates with the disorder.
To further validate our findings, we performed Sanger
sequencing of 37 variants that were identified in the exome
sequencing results but excluded after the final IBD filtration step.
Four of these variants were located in genes with biological
activities that could relate to the disorder (DAB2, IQSEC1,
KIAA1456, and ADAM28), such as vascularization, angiogenesis,
imprinting, and neurogenesis [24–27]. However, Sanger sequenc-
ing of all 37 variations, including these four genes, showed that
individual III.3 does not carry the variant, as expected from the
IBD analysis (Figure S2; Table S4). Importantly, these results
support the validity of the IBD filtration technique and provide
additional evidence supporting the absence of an etiological point
mutation in the exome.
Copy Number Variation Analysis Identified a Familial
Duplication of 14q22.3
Given the absence of point mutations, we turned to copy
number analysis using the genotype data from the genome-wide
SNP array. Our analysis revealed a 1.3 Mb duplication of 14q22.3
(chr14:57,141,867–58,495,517) in all four individuals that segre-
gated along all 8 meioses (Figure 2a). In general, CNVs of this
length are rare and typically deleterious [28]. No other detected
CNVs (.10 kb) were found to segregate with the disorder. To
increase the sensitivity, we repeated the CNV analysis and
inspected only CNVs that are shared in individuals III.1, V.2,
and V.3. We excluded individual III.3 from this analysis because
the array genotyping was performed separately and showed
greater systematic noise. This process revealed seven CNV
segments (.10 Kb) in addition to the 14q22.3 duplication.
However, all but one were also found in healthy Ashkenazi
controls from genome-wide genotyping array data [29]. The one
segment that was not present in the Ashkenazi controls was a
,37 kb duplication of a non-coding region (chr3:187,279,170–
187,316,070) that overlapped a known duplication found in
healthy Asian controls in the Database of Genomic Variants
(DGV: nssv1548729). Moreover, we did not see any evidence of
this duplication in the array data for III.3. Thus, we concluded
that the duplication of 14q22.3 is the only likely CNV that
segregates with the disorder.
In order to confirm the expected rarity of this duplication, we
evaluated its frequency in the general Ashkenazi population.
Analysis of the genome-wide genotyping array data from 942
healthy Ashkenazi chromosomes [29] returned two copies for this
Table 1. Clinical features of family members displaying HFM anomalies.
Clinical feature III.1 III.3 IV.3 V.2 V.3
Facial cleft + + + + +
Facial asymmetry + + + + +
Anotia/microtia 2 2 2 2 +
Preauricular tags + 2 + + +
Mandibular, maxillary hypoplasia + + + + +
Retrognathia 2 + 2 + +
Epibulbar dermoids 2 2 2 2 2
Cardiac anomalies 2 2 2 2 2
Renal anomalies 2 2 2 2 2
Vertebral anomalies 2 2 2 2 2
Medulloblastoma 2 2 2 2 +
doi:10.1371/journal.pone.0096788.t001
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region. In addition, no duplications were found in this region in
CNV analysis of deep whole genome sequencing data from 284
chromosomes of Ashkenazi controls sequenced by Complete
Genomics that are part of The Ashkenazi Genome Consortium
(TAGC) and 1842 chromosomes from phase I of the 1000
Genomes Project [30]. These population-specific results support a
familial variant that segregates with the disorder.
To validate our results, we performed qPCR analysis of the
duplicated region using Taqman assays (Figure 2b). Three
probes targeting genes in the duplication (OTX2OS1, EXOC5,
and NAA30) were confirmed as CN=3 (copy number) in
individuals IV.2, IV.3, and III.3. We also observed duplication
of OTX2OS1 and NAA30 in V.3 and of NAA30 in III.1,
confirming segregation of this CNV along all informative meioses
of the family. Assays targeting OTX2OS1, EXOC5, and NAA30
returned CN=2 in all HapMap controls and OTX2OS1 and
NAA30 were both CN=2 in 45 Ashkenazi control samples
(Figure S4). To validate the boundaries of the CNV, we also
targeted KTN1 and PSMA3, upstream and downstream of the
predicted CNV. Both probes returned CN=2 in affected family
members and HapMap controls (Figure 2b).
In order to evaluate the presence of the duplication in additional
HFM cases in Israel, the Craniofacial Department of Rambam
Medical Center collected DNA from 7 families that consisted of
one affected offspring and unaffected parents. Interrogation of 2
genes in the duplicated region (NAA30 and OTX2OS1) by qPCR
did not reveal any copy number changes in the seven additional
HFM cases (Figure S3). These findings suggest a distinct genetic
etiology of the disorder in our family and are consistent with
previous studies that described genetic heterogeneity [18].
However, a literature search revealed that a spectrum of genetic
lesions in the 14q22 region have been associated with various
facial anomalies. Ou et al. [31] reported a complex event of a
duplication of 11.8 Mb that fully encompasses our 14q22 region
and translocation to 13q21. Interestingly, the proband suffered a
range of clinical signs resembling HFM, including facial asymme-
try, mandibular hypoplasia, and ear defects in addition to
developmental delay, lacrimal duct stenosis, and renal anomalies.
Northup et al. [32] reported a large pericentric inversion
inv(14)(p11.2q22.3) in a proband with HFM signs, inherited from
his phenotypically normal mother. Ballesta-Martinez et al. [33]
recently published a clinical report of a 14q22 duplication in a
Spanish family with variable phenotypes resembling HFM.
Although we cannot exclude the possibility that the duplication
in our family also involved a translocation that disrupts an
etiological gene outside this region, these studies support our
findings, implicating 14q22 in craniofacial development.
Candidate Gene Prioritization in the Duplicated Segment
We sought to predict the etiological gene that contributes most
to the phenotype in an unbiased manner among the eight genes
(OTX2, OTX2OS1, EXOC5, AP5M1, NAA30, C14orf105,
SLC35F4, and C14orf37 [partial]) that reside in the duplicated
region.
First, we prioritized the genes in the duplicated region based on
the similarity of their molecular signatures to known etiological
genes of other facial malformations. We and others have
successfully identified etiological genes using this guilt-by-associ-
ation approach in previous studies of rare human disorders [34–
36]. The basis of this technique is that similar phenotypes are
caused by genes that reside in close biological modules such as the
same pathway, co-expression cluster, and shared regulatory
control (Goh et al 2007). To identify a set of disorders similar to
HFM in an unbiased manner, we used MimMiner, which ranks
clinical conditions in OMIM based on phenotypic resemblance
[37]. The top three phenotypes with similar features to HFM were
CHARGE syndrome (OMIM: 214800), VACTERL association
(OMIM: 314390), and Townes-Brocks syndrome (OMIM:
107480). In fact, HFM and TBS are both characterized by first
and second arch defects, including ear, jaw, and kidney
malformations [38]. Interestingly, a previous study also cited the
commonalities between HFM, CHARGE, and VACTERL [39],
adding additional support to the MimMiner prediction. We then
compared the biological signatures of all coding genes in the
duplicated region to CHD7, ZIC3, and SALL1, the corresponding
genes of the three syndromes. To increase the robustness of our
analysis, we tested these similarities using two gene prioritization
tools: Endeavour [40] and ToppGene [41]. These algorithms
utilize different biological datasets and employ distinct prioritiza-
tion procedures. These two algorithms independently ranked
OTX2 as the gene with the closest molecular signature to other
facial anomalies (Figure 3a).
Disease-associated genes can be more uniquely expressed in
affected tissues than in those that are unaffected [42,43]. Thus,
analysis of expression patterns could help to stratify the
contribution of the genes in the region to the pathology. We used
publicly available expression array profiles of mouse embryonic
tissue to compare the expression of the duplicated genes in affected
versus unaffected tissues. Specifically, we analyzed expression
levels in the pharyngeal arches at embryonic day 10.5 and in the
entire head at E13.5. These developmental stages approximately
overlap with the suggested critical periods for the HFM
developmental perturbation in humans [1]. We contrasted these
expression levels with the expression profiles of liver, heart, and
lung (E13.5) and heart and urogenital epithelium (E10.5) since
these tissues are rarely implicated in HFM. At E10.5, the arrays
contained data for Otx2, Ap5m1, Naa30, and Slc35f4. At E13.5,
Table 2. Exome filtering steps.
Filtering steps III.1 V.2 V.3
Exonic variants 22,252 22,746 23,175
Non-synonymous 9,552 9,839 10,072
Rare variants* 560 662 665
Variants in IBD segments 84 90 72
Shared variants 40
Shared with III.3 0
*Rare variants are defined as those that appear at a frequency of less than 0.1% in dbSNP.
doi:10.1371/journal.pone.0096788.t002
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the arrays contained data for Otx2, Otx2os1, Exoc5, Ap5m1,
Naa30, and Slc35f4. The expression profiles showed that Otx2
tends to be more highly expressed in the affected tissues than other
duplicated genes at E10.5 and E13.5 compared to any of the
unaffected tissues (Figure 3b).
Finally, we also evaluated the general sensitivity of the genes in
the region to duplication. Huang et al. [44] developed a gene-level
classifier that compares evolutionary, functional, gene-structure,
and interaction patterns between haplosufficient and haploinsuffi-
cient genes. Interestingly, they found higher expression and tissue
specificity of haploinsufficient genes early in development.
Although the classifier predicts the probability of haploinsuffi-
ciency, it is also useful for detecting genes with increased dosage
sensitivity (M. Hurles, personal communication, August 2013).
Three of the duplicated genes were included in their classifier:
OTX2 had the highest sensitivity score (0.9) followed by NAA30
(0.474) and SLC35F4 (0.418) (Figure 3c). To summarize, all of
our in silico analysis techniques suggested that duplicated OTX2 is
the most likely pathological gene in our HFM cases.
Discussion
We conducted a systematic study of familial HFM that
implicates OTX2 dosage sensitivity in the disorder. OTX2
encodes a transcription factor that plays a critical role in
craniofacial development and anterior brain morphogenesis.
OTX2 homologs in model organisms are expressed in a complex
spatial, temporal, and gradient-specific manner that is required for
correct antero-posterior patterning and craniofacial development
[45]. These expression patterns are influenced by tissue-specific
feedback from other genes and by auto-regulation, which may
introduce compensatory mechanisms that depend on the activity
of other genes. Perturbations in relative expression levels could
explain the tissue-specific pathologies as well as the highly variable
phenotype and incomplete penetrance of the disorder in our cases.
Loss-of-function studies in mice showed that null embryos fail to
develop the anterior head and die during embryogenesis while
Otx2+/2 mice exhibit a range of severe craniofacial anomalies,
including micrognathia, agnathia, anophthalmia, and head
narrowing with no involvement of the auricle [46]. The severity
of the phenotype depends on the genetic background [47],
Figure 2. The 14q22 duplicated region. (a) Raw intensity plots of the duplicated region (contained between the dotted lines) in the four affected
individuals and 4 Ashkenazi controls from [29]. The signals represent the number of standard deviations of the probes from the mean value. The
suspected copy number gain is marked by dotted vertical lines. The red line is a moving average with a window of 20 probes. (b) qPCR results of the
affected family and two HapMap controls for genes in the duplicated region (OTX2OS1, EXCO5, and NAA30) and two flanking genes (KTN1 and
PSMA3) are consistent with the array results.
doi:10.1371/journal.pone.0096788.g002
Figure 3. Prioritization of genes in 14q22. (a) Ranking similarity of the molecular signatures of the genes in the duplicated region to causal
genes in CHARGE, VACTERL, and Townes-Brocks using Endeavour and ToppGene. The average rank of both tools is indicated in red. (b) Ranking of
expression levels in pharyngeal arches (PA) compared to heart and urogenital epithelium (UG) [37] in E10.5 and expression in the head compared to
liver, heart, and lung in E13.5 for genes in the duplicated region. Comparative expression ranked OTX2 highest in the affected tissues in all conditions.
(c) Ranking of dosage sensitivity predictions for 3 of the duplicated genes [44].
doi:10.1371/journal.pone.0096788.g003
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consistent with the wide spectrum of phenotypes associated with
loss of function in humans. Temporal loss of one copy of Otx2
during mouse embryogenesis up to E12.5 results in haploinsuffi-
ciency that leads to significantly low survival rates and abnormal
head development, including reduction or absence of the
forebrain, eyes, and jaw [45]. OTX2 hemizygous deletions and
non-synonymous point mutations have been reported in patients
with severe ocular malformations, developmental delays, and
hypopituitarism, symptoms that are not seen in our pedigree [48–
50]. OTX2 loss-of-function mutations are associated with a wide
phenotypic spectrum and the absence of such anomalies in our
subjects suggests a different set of pathologies resulting from
OTX2 duplications.
The OTX2 germline duplication in our subjects suggests a
potential link to the medulloblastoma of the proband. OTX2 is a
known oncogenic driver of medulloblastoma [51]. Focal duplica-
tions and overexpression of this gene are prevalent in subclasses C
and D of medulloblastoma [52]. Analysis of her tumor revealed an
additional loss of heterozygosity on chromosome 17q [20] that is
exclusively associated with subclasses C and D [52]. The potential
biological link between OTX2 duplications in hemifacial micro-
somia and medulloblastoma raises the possibility of their
comorbidity. While confirming this hypothesis will require the
analysis of a large number of cases, we suggest clinicians be aware
of the possibility of increased risk for medulloblastoma in HFM
cases with OTX2 duplications.
Our study adds to the existing literature in multiple ways. First,
we investigated the largest HFM pedigree to date, increasing the
confidence of our genetic analysis. Second, it is the first HFM
study to combine whole exome sequencing analysis with the
scanning of copy number variants. This approach increases the
likelihood that the duplicated region is indeed the etiological site.
Third, we present data from more than 1000 chromosomes of
unaffected controls, which strongly diminishes the likelihood that
the duplication is a polymorphism that segregates in the
population. Fourth, we report an unbiased search using different
systems biology approaches to find the most likely pathological
gene in the region. These analyses implicated OTX2 as the most
likely causal gene. Fifth, our findings suggest a potential shared
etiology for HFM and medulloblastoma.
Determining the causative gene for HFM can promote
stratification of cases based on the molecular pathology, guide
clinical care, offer reproductive alternatives to families that carry
an OTX2 duplication, and facilitate definitive diagnosis, which is
currently inadequate for HFM. Importantly, implicating OTX2 in
this disorder can improve understanding of the basic molecular
processes that underlie normal and pathological craniofacial
development.
Materials and Methods
Human Subject Research
This study was approved by the Helsinki Committee at the
Rambam Medical Center (Haifa, Israel), the Israeli Ministry of
Health, and MIT’s Committee on the Use of Humans as
Experimental Subjects. Written consent for sample collection
and use in the study was approved by both committees and
obtained from all participants. Informed consent was obtained
from guardians on behalf of minors enrolled in the study. Subjects
were informed of the terms of the PLOS open-access license and
subject IV.3 gave written informed consent to publish photo-
graphs. Additionally, photos of the proband (V.3) were previously
published [20]. MIT’s IRB (COUHES) approved this consent
procedure.
Coordinate System
All alignment and genomic coordinates in this manuscript are
reported according to hg19. All coverage values are reported after
removing PCR duplicates.
DNA Collection
All DNA was derived from whole blood using standard
procedures.
Exome Sequencing
Paired-end library preparation and exome enrichment were
done following a streamlined protocol written by Blumenstiel et al.
[53], using Agilent’s SureSelect All Exon V.2 kit, which covers
98.2% of exons and splice sites, according to the Consensus CDS
(CCDS) database [54]. Sequencing was performed at Counsyl
(South San Francisco, USA) on a single flow cell on the Illumina
HiSeq2000 with 100 bp paired end reads (V.2 and V.3 on 3 lanes
and III.1 on 2 lanes).
To increase the accuracy of our analysis, we processed the
sequencing data with two distinct pipelines. First, we iteratively
aligned the sequence reads with Bowtie [55] and with BWA
[56]. Multi-mappers were excluded. Reads that failed to align
were repeatedly trimmed by 10 bp down to a minimum of
36 bp and were processed in an additional round of alignment.
The BAM files of all unique mappers from the different
alignment rounds were merged and PCR duplicates were
removed using SAMtools [57]. Variant calling of Bowtie-
aligned reads was done using VarScan v2.8.8 [58] with
mpileup2cns and the following options: —min-coverage 5 —
min-freq-for-hom 0.9 —p-value 0.97 —strand-filter 1. After
alignment using BWA, variant calling was done using the
Genome Analysis Toolkit (GATK) [59], following the recom-
mended workflow and filtering of low quality variant calls. In
addition, we used lobSTR 1.0.6 [60] to examine short tandem
repeat variations in the exomes of III.1. V.2, and V.3. We
filtered for STRs genotyped in all three samples with at least
56 coverage in each, that fell within regions shared by all
samples with IBD= 1, and falling within annotated Refseq
genes. Six loci were called as non-reference in all three
samples. For each locus, the non-reference allele was found in
at least one healthy control from a panel of more than 30
healthy controls, mainly of European descent.
Validation by Sanger Sequencing
We used Primer3 [61] to design primers flanking candidate
variants (+/2100 bp upstream and downstream). We excluded
primers that generated more than one in silico PCR product on the
UCSC Genome Browser [62]. Sanger sequencing was done on an
ABI 3730 DNA Analyzer.
Genome-Wide Human SNP Array 6.0
Genomic DNA was extracted from peripheral blood leukocytes
using standard methods. We performed genotyping of subjects
III.1, III.3, V.2, and V.3 using the Affymetrix SNP 6.0 Array. We
analyzed the 4 cases together with 471 unrelated Ashkenazi
controls [29] (NCBI GEO GSE23636) using the Affymetrix
genotyping console (v 4.1.3) and Birdsuite [63] for genotype
calling.
Investigating exonic variations
Annotation of exonic variations was done using SeattleSeq
Annotation 137 [23] and minor allele frequencies in dbSNP were
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taken from BioQ [64]. Filtering of variants was done using
BEDTools [65] and custom Perl scripts (available upon request).
IBD Calculations
We used the Affymetrix genotyping console (v 4.1.3) for
genotype calling of our 4 subjects together with 50 randomly
selected individuals from the Ashkenazi controls (Bray 2010).
Initial data analysis and selection of SNPs were carried out using
PLINK [66]. We selected subsets of SNPs with MAF.0.1 that are
in approximate linkage equilibrium. This was carried out using the
pairwise correlation method for LD pruning implemented in
PLINK. We used the following parameters: window size = 50,
step = 5, r‘2 threshold = 0.35. The pruned data contained
123209 SNPs.
We used the pruned data as input to MERLIN [67] for pairwise
IBD inference, with genetic map positions of 1 Mbp=1 cM.
Candidate IBD regions were selected based on pair-wise IBD
probabilities. We marked all regions for which IBD probabilities
for sharing an allele for all pairs of cases in the data were inferred
to be higher than 0.5. We then extended the IBD region to include
the tips of the chromosomes for cases when IBD=1 was detected
in the first or the last SNP on the chromosome.
Taqman CNV Assays
We purchased custom Taqman probes to interrogate the CNV
and flanking regions (probe start locations in NCBI build 37:
chr14:20811565, chr14:56099993, chr14:57267695, chr14:572709
23, chr14:57272149, chr14:57277101, chr14:57328402, chr14:57
476529, chr14:57597148, chr14:57700715, chr14:57868427,
chr14:58725337, chr17:44203062). Reactions were carried out in
10 ul, with 10 ng genomic DNA and 10 ng reference DNA
(RnaseP), in 4 replicates. Copy number was determined using the
delta delta Ct method and CopyCaller v2.0 with HapMap samples
NA06991 and NA11832 as calibrators. The OTX2 probes that
were purchased from ABI failed to work despite repeated attempts.
They produced non-Mendelian inheritance patterns for trios and
reported deletions of the region in normal healthy controls. We
therefore excluded these probes from the analysis.
Prioritization using Biological Signatures
Endeavour is available at: http://homes.esat.kuleuven.be/
,bioiuser/endeavour/tool/endeavourweb.php and ToppGene is
available at: http://toppgene.cchmc.org/prioritization.jsp. In En-
devaour, we used the following features: CisRegModule, Expres-
sion – SonEtAl, Expression – SuEtAl, Interaction – Bind,
Interaction – BioGrid, Interaction – Hprd, Interaction – InNetDb,
Interaction – Intact, Interaction – Mint, Interaction – String,
Motif, Precalculated – Ouzounis, and Precalculated – Prospectr.
In ToppGene, we used the following features: Domain, Pathway,
Interaction, Transcription Factor Binding Site, Coexpression,
Computational, MicroRNA, Drug, and Disease.
Expression analysis of genes in the region
Expression profiles were derived from the following experiments
in GEO [68]: Pharyngeal arches E10.5: experiment GDS3803
with subjects GSM448013, GSM448014, GSM448015, GSM44
8016, and GSM448017. Urogenital epithelium E10.5: experiment
GDS3173 with subjects GSM257875, GSM257932, and GSM2
57933. Heart E10.5: experiment GDS627 with subjects GSM2
5150, GSM25151, GSM25152. Head E13.5: experiment GDS2
874 with subjects GSM212558, GSM212560, GSM212562, and
GSM212564. Liver E13.5: experiment GDS2693 with subjects
GSM177034, GSM177035, and GSM177036. Lung E13.5:
experiment GSM290632 with subject GSE11539.
All experiments were carried out on the Affymetrix Mouse
Expression Array 430. The pharyngeal arches experiment
reported results only from the A array and all the others reported
both the A and B arrays. Therefore, in all E10.5 comparisons, we
restricted the analysis only to genes that are on the A array.
Based on experimental details in GEO or associated publica-
tions, the genetic background of all mice was concluded to be
C57BL/6, with the exception of GDS3173 (E10.5 urogenital
epithelium), the background of which was not documented.
We downloaded the full soft file of each experiment from
GEO, extracted the data from the relevant subjects, and
normalized the expression data to range from zero to one for
each subject. Experiments with multiple sets were averaged
inside the same condition. Then, genes with more than one
probe were averaged inside the same condition. Finally, we
divided the expression of each gene in the affected tissue
(pharyngeal arches and head) by expression in the control
tissues (liver, lung, heart, and urogenital epithelium) and
ranked the expression levels.
Dosage sensitivity analysis
Data was taken from Dataset_S1.txt of Huang et al. [44].
Access to the sequencing and array data
The sequencing and genotyping data from this study are
available on dbGAP (http://www.ncbi.nlm.nih.gov/gap) and
http://erlichlab.wi.mit.edu/hfm (please refer to the website for
Terms and Conditions).
Appendix
Our working hypothesis was that any point mutation that
causes HFM will have a minor allele frequency (MAF) of less
than 0.1% in large sequencing projects. We based our
hypothesis on the fact that HFM is estimated to occur at a
frequency of 1:5,000–1:20,000 births in the general population.
Segregation analysis by Kaye et al. (1992) predicted that the
sum of minor allele frequencies of all HFM causative genes is
1:3000 (after taking into account penetrance levels). The MAF
of a single etiological variant is even smaller, since previous
linkage analysis identified at least three non-overlapping
segments.
Moreover, the affected family is of Ashkenazi heritage. With
the limited gene flow between the Ashkenazi population and
other European populations, the causal mutation in our family
is expected to be at even smaller frequencies in these large
sequencing projects due to the low sampling rates of Ashkenazi
Jews. To confirm this assumption, we compared the MAFs of
more than 50 recessive mutations associated with Ashkenazi
genetic disorders to the Exome Sequencing Project where we
obtained most of the control chromosomes used in our
analysis. These mutations are found at frequencies of 1/25
to 1/70 in the Ashkenazi population, which is much higher
than the expected frequency of a causative mutation of HFM.
We found that the MAFs of these mutations were diluted by
factors of more than 206 to 506 in ESP compared to the
Ashkenazi population. Even if the causal mutation is found at a
very unlikely rate of 1% in Ashkenazim, we expect it to be ,
0.05% in ESP. Thus, a 0.1% threshold is highly unlikely to
miss the causative mutation.
Similarly, we excluded variants that were seen at least twice
in 42 unaffected Ashkenazi chromosomes. The probability to
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see a mutation with a true MAF of 0.1% in two individuals
from this cohort is ,161023. Therefore, there is a very small
risk of excluding the causative mutation using this MAF cutoff.
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